Immunotherapy in Chemorefractory Endometrial Cancer: Ray of Hope?

IntroductionMolecular profiling and targeted treatment are the new approach in management of endometrial cancer.Immunotherapy has shown promising results in recurrent advanced previously treated endometrial cancer, but its role as a part of primary treatment is yet to be establised.MethodsIn this article we are reporting a case of MSI-H advanced endometrial cancer with Pembrolizumab as a third line therapy prior to attempting complete cytoreduction.ResultsAdditon of Pembrolizumab resulted in complete response to treatment in a chemorefractory advanced endometrial cancer.ConclusionsImmunotherapy is a viable novel therapeutic option to treat advanced endometrial cancer in select cases.